Trial Profile
Long-term study of K-877 add-on to HMG-CoA reductase inhibitor in patients with dyslipidemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 May 2016
Price :
$35
*
At a glance
- Drugs Pemafibrate (Primary) ; HMG-CoA reductase inhibitors
- Indications Dyslipidaemias
- Focus Therapeutic Use
- Sponsors Kowa
- 08 May 2015 New trial record